BioStem Technologies, Inc. (BSEM)
USD 8.3
(1.22%)
USD 8.3
(1.22%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 16.68 Million USD | 142.69% |
| 2022 | 6.87 Million USD | 58.38% |
| 2021 | 4.34 Million USD | 72.14% |
| 2020 | 2.52 Million USD | -4.13% |
| 2019 | 2.63 Million USD | 158.59% |
| 2018 | 1.01 Million USD | 209.62% |
| 2017 | 328.52 Thousand USD | -44.53% |
| 2016 | 592.29 Thousand USD | 290.86% |
| 2015 | 151.53 Thousand USD | 385.8% |
| 2014 | 31.19 Thousand USD | 103.76% |
| 2013 | 15.3 Thousand USD | -98.1% |
| 2012 | 806.74 Thousand USD | -40.83% |
| 2011 | 1.36 Million USD | 8.01% |
| 2010 | 1.26 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 41.9 Million USD | 266.24% |
| 2024 Q2 | 74.49 Million USD | 77.77% |
| 2023 FY | 16.68 Million USD | 142.69% |
| 2023 Q2 | 1.06 Million USD | 85.45% |
| 2023 Q4 | 11.44 Million USD | 217.91% |
| 2023 Q3 | 3.59 Million USD | 236.87% |
| 2023 Q1 | 576.1 Thousand USD | -27.36% |
| 2022 Q3 | 1.14 Million USD | -46.9% |
| 2022 FY | 6.87 Million USD | 58.38% |
| 2022 Q4 | 793.08 Thousand USD | -30.78% |
| 2022 Q1 | 2.77 Million USD | 127.93% |
| 2022 Q2 | 2.15 Million USD | -22.34% |
| 2021 FY | 4.34 Million USD | 72.14% |
| 2021 Q4 | 1.21 Million USD | 1.69% |
| 2021 Q1 | 952.5 Thousand USD | -8.22% |
| 2021 Q2 | 970.51 Thousand USD | 1.89% |
| 2021 Q3 | 1.19 Million USD | 23.52% |
| 2020 Q1 | 777.36 Thousand USD | 16.65% |
| 2020 Q3 | 467.62 Thousand USD | 95.8% |
| 2020 Q4 | 1.03 Million USD | 121.94% |
| 2020 FY | 2.52 Million USD | -4.13% |
| 2020 Q2 | 238.82 Thousand USD | -69.28% |
| 2019 Q1 | 532.78 Thousand USD | 0.0% |
| 2019 FY | 2.63 Million USD | 158.59% |
| 2019 Q4 | 666.39 Thousand USD | -7.8% |
| 2019 Q3 | 722.77 Thousand USD | 2.03% |
| 2019 Q2 | 708.37 Thousand USD | 32.96% |
| 2018 Q1 | 63.92 Thousand USD | 9.22% |
| 2018 FY | 1.01 Million USD | 209.62% |
| 2018 Q2 | 35.31 Thousand USD | -44.75% |
| 2017 Q3 | 55.28 Thousand USD | -34.71% |
| 2017 Q4 | 58.52 Thousand USD | 5.86% |
| 2017 FY | 328.52 Thousand USD | -44.53% |
| 2017 Q1 | 114.72 Thousand USD | 32.7% |
| 2017 Q2 | 84.67 Thousand USD | -26.19% |
| 2016 Q1 | 149.09 Thousand USD | -1.61% |
| 2016 Q2 | 213.99 Thousand USD | 43.53% |
| 2016 Q3 | 208.09 Thousand USD | -2.76% |
| 2016 Q4 | 86.45 Thousand USD | -58.46% |
| 2016 FY | 592.29 Thousand USD | 290.86% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | 151.53 Thousand USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 151.53 Thousand USD | 385.8% |
| 2014 Q4 | 31.19 Thousand USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | 31.19 Thousand USD | 103.76% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 Q3 | 15.3 Thousand USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 15.3 Thousand USD | -98.1% |
| 2013 Q4 | - USD | -100.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | 806.74 Thousand USD | -40.83% |
| 2011 FY | 1.36 Million USD | 8.01% |
| 2010 FY | 1.26 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -21934.5% |
| Evofem Biosciences, Inc. | 18.21 Million USD | 8.413% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 86.43% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -763.634% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -5.785% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -94590.455% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | 22.314% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -25285.536% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -182.708% |
| Marizyme, Inc. | 645.81 Thousand USD | -2483.64% |
| Genus plc | 668.8 Million USD | 97.505% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 93.198% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -16754.966% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -3967.974% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -21636.826% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -42122.291% |
| MultiCell Technologies, Inc. | 49.32 USD | -33830810.381% |
| ONE Bio Corp. | 52.29 Million USD | 68.094% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | 66.442% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -34021.483% |
| Q BioMed Inc. | 284.35 Thousand USD | -5767.87% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | 43.625% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 88.501% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -2891.771% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -23736.293% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -2433.85% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.886% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -1670110.711% |
| Enzolytics Inc. | 52.79 Thousand USD | -31503.54% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -2641.942% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 98.639% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -11797.581% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -2602.598% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 98.013% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -1572.343% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | 65.493% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -6953.35% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -6953.35% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -1118.802% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -3422.134% |
| SYBLEU INC | 11.69 Thousand USD | -142559.071% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -114.218% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -128249.269% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -42105.203% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -401.063% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -150.344% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -1505.91% |
| Gelesis Holdings, Inc. | 25.76 Million USD | 35.245% |
| CSL Limited | 14.8 Billion USD | 99.887% |
| Cellectis S.A. | 755 Thousand USD | -2109.987% |